Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives

Published: Tuesday, April 02, 2013
Last Updated: Tuesday, April 02, 2013
Bookmark and Share
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.

Building on an earlier collaboration, Agilent and the university’s Graduate School of Analytical Science and Technology (GRAST) will establish the Asia Glycomics Education Center to support collaborative university/industry education and cross-training. The university will develop and administer training programs for various methods of glycan analysis, which will be made available without charge to scientists and researchers endorsed by Agilent in South Korea and the South Asia-Pacific region.

“Since we first started collaborating with Agilent in 2011, our university has enjoyed access to the latest analytical and scientific technologies for research in glycomics. Our highly talented team at GRAST, led by professor Hyun-Joo An, has made a number of significant findings, which have been shared with the global scientific community through papers and speaking engagements,” said university president Sang-Chul Jung. “This lives up to our university’s motto—‘Creativity, development, and service to the community’—and we are pleased to further this collaboration with Agilent.”

“In science, discovery is a long and arduous road dependent on the best people, process and technology,” said Rod Minett, general manager of Agilent’s Life Sciences Group in South Korea and the South Asia-Pacific region. “For this collaboration with Chungnam National University, we are going into the next phase of our journey to develop and enhance the biosimilars industry, which will help scientists develop new treatments to cure or prevent diseases.”

Collaborative research between Agilent and leading academic researchers worldwide serves as the company’s means of giving back to communities in which it does business. At the Asia Glycomics Education Center, Agilent will install a state-of-the-art Agilent 6540 Quadrupole Time-of-Flight with Chip/2D nanoHPLC system. The new system will be used to develop novel applications or analytical methods in the field of glycomics and glycoproteomics.

 “Around the world, we have seen greater interest among scientists and researchers in the area of glycomic research,” said professor An. “Through our research, we are often pushing the frontiers of science and the capabilities of our analytical instruments. We are thrilled to continue this partnership with Agilent.”

Professor An, who heads the Asia Glycomics Education Center, will continue to work with Dr. Rudolf Grimm, Agilent’s director of science and technology and manager of collaborations in the Asia-Pacific region. “This is an important next-step for both Agilent and Chungnam National University as we continue to build talent and drive innovations and discoveries in the field of glycomics using industry-leading analytical solutions,” said Dr. Grimm.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Announces Agreement with Picometrics Technologies
Agilent to provide Picometrics' biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry.
Friday, January 17, 2014
Agilent, University of Rouen and A*STAR’s Bioprocessing Technology Institute to Collaborate
The collaborations aims to further innovation in biopharmaceuticals and glycomics through developing tools to effectively analyze biologics and vaccines.
Thursday, May 23, 2013
Agilent Technologies, University of Rouen and A*STAR’s Bioprocessing Technology Institute Collaborate
Organisations will work together to further innovation in biopharmaceuticals and glycomics.
Thursday, May 23, 2013
Agilent Technologies Introduces Verified Dissolution Components for Pharmaceutical Market
Agilent Technologies Inc. introduced a new series of verified dissolution components, including molded vessels as well as paddle and basket shafts.
Wednesday, May 15, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Merck-Serono Adopts Agilent Technologies’ Electronic Lab Notebook for Biology Research
Agilent Technologies Inc. have announced that Merck-Serono, a division of Merck KGaA, Darmstadt, Germany, has selected the Agilent OpenLAB Electronic Lab Notebook (ELN) to enhance scientific collaboration globally throughout R&D for finding new small molecules and biopharmaceuticals.
Tuesday, November 23, 2010
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos